Oral AZD5438 is a clinically translatable otoprotectant against cisplatin-induced hearing loss
Cisplatin-based chemotherapy causes hearing loss in 40–60 % of all patients, yet effective preventative options remain limited. Building on prior animal studies, we demonstrate that oral administration of AZD5438, a potent and selective CDK2 inhibitor, provides dose-dependent protection against hear...
Kaydedildi:
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier
2026-01-01
|
| Seri Bilgileri: | Neoplasia: An International Journal for Oncology Research |
| Konular: | |
| Online Erişim: | http://www.sciencedirect.com/science/article/pii/S1476558625001307 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|